<DOC>
	<DOCNO>NCT03018925</DOCNO>
	<brief_summary>This study aim characterize change intestinal microbiota pattern associate use golimumab order determine intestinal microbiota marker may correlate golimumab therapeutic effect patient naïve &amp; non-naïve anti-TNF treatment</brief_summary>
	<brief_title>Golimumab Effect Modulation Gut Microbiota Ulcerative Colitis</brief_title>
	<detailed_description>Golimumab effect modulation gut microbiota Ulcerative Colitis . Pilot Study . 1 . BACKGROUND Recently , consistent body evidence indicate gut microbiota ability modulate direct host immune response consider one pivotal factor modulate delicate balance health disease digestive disease . In case inflammatory bowel disease ( IBD ) , gut microbiota central role maintain microbiological homeostasis patient . Recent study describe existence different pattern intestinal microbiota patient IBD healthy individual . The alteration microbiological pattern associate disease know dysbiosis directly relate degree inflammation intestinal mucosa , , thus , clinic status : great dysbiosis , great clinical correlation disease state , gut microbiota direct marker state colonic inflammation . The state dysbiosis measure different microbiological index total population bacteria colon . Changes rate index parameter measure characterize gut microbiota patient . In case ulcerative colitis ( UC ) study show intestinal microbiota central factor maintain balance deep remission presence flare-up . Despite advance , in-depth knowledge gut microbiota interact intestinal mucosa alters intestinal barrier molecular/genetic mechanism still unknown . Some gene associate cofactor identify exact mechanism interaction yet describe . The data indicate , presumably , mechanism regulation multifactorial process . In way , deep understanding gut microbiota interaction host colon great interest , order shape future IBD treatment , especially UC . Thus , IBD patient ' intestinal microbiota could either therapeutic target ( fecal transplantation ) consider adjustable adjuvant immunomodulators The group anti-TNF drug recently incorporate therapeutic arsenal UC , case change natural curse disease . However , still unknown drug modulate intestinal microbiota interfere , although , probably , develop role . Recent result study group , indicate enter clinical remission , gut microbiota modify pattern less related dysbiosis . Given increase importance use anti-TNF drug , great interest discriminate pattern associate dysbiosis relate healthy mucosa , modify result use anti-TNF drug . In way , previous result group analyze change intestinal microbiota associate Adalimumab anti-TNF drug treatment show progression patient remission , mucosal dysbiosis pattern change . On hand , group also observe drug treatment failure , gut microbiota return pattern close dysbiosis . For reason , gut microbiota could consider excellent indicator real drug effectiveness patient . Regarding Golimumab , recently introduce anti-TNF drug therapy UC , still unknown able modulate intestinal microbiota remission-related pattern , since date available study relationship Golimumab phenomenon . The use prebiotics probiotic show effectiveness adjuvant treatment UC . For reason , characterization gut microbiota pattern important develop new strategy adjuvant ability modulate , especially patient receive anti-TNF drug achieve complete remission . Similarly recent study , suggest modulation gut microbiota could optimize response outcome patient treat Golimumab . In conclusion , base current trend literature , suggest modulation intestinal microbiota characterization remission-related pattern , huge impact management patient UC . Moreover , modulation gut microbiota together anti-TNF drug effectiveness could promise field management inflammatory bowel disease . 2 . HYPOTHESIS AND OBJECTIVES 2.1 Hypothesis 1 . Intestinal microbiota profile change accord UC activity . 2 . The Intestinal microbiota profile correlate clinical remission represent stable intestinal microbiota biodiversity . 3 . Assess Intestinal Microbiota useful tool measure Golimumab effectiveness patient naïve anti-TNF treatment patient recurrent anti-TNF treatment . 2.2 Objectives 1 . To correlate clinical remission Golimumab treatment normal intestinal microbiota profile biodiversity 2 . To characterize pattern intestinal microbiota associate use Golimumab temporal dynamic microbial change . 3 . Assess effect golimumab degree colic dysbiosis treatment Ulcerative Colitis naive Golimumab . 3 . MATERIAL AND METHODS 3.1 Type study/design Multicenter transversal pilot Study 3.2 Study population The propose study include 15 UC anti-TNF naïve patient Hospital Universitari Dr. Josep Trueta . Investigators consider remission patient endoscopic Mayo score ≤1 , activity index score , Mayo= 0 point . 3.3 Interventions NOTE : `` The assignment patient particular therapeutic strategy predetermine advance study protocol , instead clinical practice . Plus , decision prescribe particular drug clearly unlinked decision include patient study . Patients undergo intervention , whether diagnostic monitoring , usual clinical practice , epidemiological method shall use analysis data collect '' 3.3.1 Treatments GOLIMUMAB induction 200mg week 0 , 100mg week 2 . Under 80kg , follow treatment 50mg/month , 100mg/month patient 80kg , clinical practice . 3.4 Variables 3.4.1 Demographic variable - Age express year ( ) - Sex Male ( M ) / Female ( F ) - Body Mass Index - Ethnic : Caucasian/ African/ Asiatic/ American - Tobacco : YES / NO / EX-Smoker - Age UC diagnosis express year ( ) - Familiar Antecedents ( YES/NO ) kind disease ? - Localization Left ( L ) / Righ ( R ) / extend ( E ) 3.4.2 Clinical variable - Mayo clinic score ( Clinical colitis activity index ) ( Schroeder KW et al . NEngl J Med 1987 ; 317 : 1625-9 ) . Score range : 0-9 point - CRP ( C-reactive protein ) : blood C-reactive protein concentration ( mg/L ) - Faecal calprotectin : stool sample express concentration calprotectin ug g feces ( ug/g ) - Standard Analysis : Hemoglobin : blood hemoglobin concentration ( g / dl ) Platelets : blood platelet concentration ( x103/ ul ) Leucocytes : blood leucocyte concentration ( x103/ ul ) Albumin : blood albumin concentration ( g / dl ) Creatinine level : blood creatinine concentration ( mg/ dl ) 3.4.3 Endoscopic variable • Mayo ( Endoscopic score Ulcerative Colitis ) ( Schroeder KW et al . 1987 ) . Mayo Endoscopic Score base Endoscopic Findings . Mayo Score range 0 3. Note : Investigators send image centralize digital platform , Mayo score assess 2 independent professional order minimize inter-observer bias . 3.4.4 Microbiological variable - Operational Taxonomic Units ( OTUs ) - Abundance bacterial load . 3.5 Methods The propose study include 15 UC patient 18 year informed consent sign , treatment anti-TNF accord clinical practice . All screen opportunistic infection . Patients anti-TNF naïve patient . Stool sample collect start Anti-TNF treatment ( M0 ) , every 3 month ( M1 , M2 , M3 M4 ) complete study . The monitoring period one year . Investigators collect demographic variable ( age , sex , tobacco , age diagnosis , localization , … ) , clinical data ( Mayo clinical score , CRP , albumin , hemoglobin , creatinine , leucocytes , platelets… ) , microbiological variable M0 , M1 , M2 , M3 &amp; M4 . Also , 4 calprotectin sampling ( baseline , week12 , 6 month end study clinical practice ) Mayo endoscopic index ( baseline end monitoring period clinical practice ) . Follow-up visit also take place within routine clinical practice . For good follow-up evolution patient , investigator perform additional test include routine clinical practice rectosigmoidoscopy week 12 start Anti-TNF treatment . Investigators consider remission patient endoscopic Mayo score ≤1 , activity index score , Mayo clinical score =0 point . Moreover , depend evolution patient , additional test also perform routine clinical protocol monitoring period . NOTE : Any test perform study / additional testing routine clinical practice accord clinical judgment criterion physician . 3.5.1 Sample process DNA Extraction : Before microbiological analysis , genomic DNA 16 RNA gene extract use NucleoSpin® Soil Kit ( Machery-Nagel GmbH &amp; Co. , Germany ) . DNA concentration determine Qubit® BR ( Invitrogen ) Kit . Bacterial 16S rRNA Gene Amplification Pyrosequencing For pyrosequencing purpose , 16S rRNA gene partially amplify extracted genomic DNA use universal bacterial primer GC-357F 5'- CGCCCG CCGCGCCCCGCGCCCGGCCCGCCGCCCCCGCCC- CCT ACG GGA GGC AGC AG-3 ' ( 341Y357 ) 907R 5'-CCG TCA ATT CCT TTG AGT TT-3 ' ( 907Y926 ) . PCR perform GeneAmp PCR System ® 2700 ( AppliedBiosystems ) ) . Then purify PCR product kit Ampure ( Agencourt AMPure , Beckman Coulter Inc ) , quantify PCR product Qubit® BR ( Invitrogen ) Kit . The pyrosequencing perform 454 Life Genome Sciences Sequencer FLX . Sequence Editing Analysis High-quality consensus sequence obtain manually refine Bioedit software package . Alignments carry ClustalW24 software . Consensus sequence compare GenBank Ribosomal Database Project use BLASTN 2.2.10 . Sequences group number operational taxonomic unit phylotypes DOTUR program26 use farthest neighbor method precision level 0.01 , i.e. , 99 % minimum similarity pair sequence belong phylotype , distance matrix Jukes-Cantor correction calculate DNADIST program Phylip software package . 3.6 Statistical analysis Statistical analysis perform SPSSx version 11.0 . Significance distance group check use analysis variance . Pearson_s x2 test use compare prevalence genus specie . Clinical laboratory data correlate value quantitative microbial index use Receiver Operating Characteristic ( ROC ) curve .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>&gt; 18 year Signed informed consent AntiTNF naïve Screening opportunistic infection Active tuberculosis another chronic infection Antibiotic treatment prior 1 month Probiotics &amp; Prebiotics Gestation lactation Heart disfunction Colectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>